Pulmonary Hypertension Due to Lung Diseases and Hypoxia

Cardiovascular
0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
Prospective study assessmentsN/A1 trial
Active Trials
NCT06388421Recruiting1,000Est. Nov 2030

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
2030
United TherapeuticsProspective study assessments

Clinical Trials (1)

Total enrollment: 1,000 patients across 1 trials

NCT06388421United TherapeuticsProspective study assessments

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Start: Jan 2025Est. completion: Nov 20301,000 patients
N/ARecruiting

Related Jobs in Cardiovascular

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 1,000 patients
1 companies competing in this space